
PIPR Stock Forecast & Price Target
PIPR Analyst Ratings
Bulls say
Piper Sandler has experienced a substantial increase in inbound fundraising related to continuation vehicles, estimated conservatively at 400%, signaling strong market demand and growth potential. The firm's productivity per senior banker is anticipated to improve from approximately $6 million to over $8 million, driven by a diversified business model and significant enhancements in service offerings. Additionally, Piper Sandler’s strategic position in the middle markets and its focus on private equity, which has been growing at roughly double the rate of the broader investment banking sector, further bolster its revenue prospects and operational resilience.
Bears say
Piper Sandler Cos is currently facing challenges in its healthcare sector, which experienced a year-over-year decline in 2024, contrasting with growth in other areas like financials. A deteriorating macroeconomic environment poses risks to the firm's overall business activity, potentially impairing revenue and earnings, particularly in the context of sluggish biotech valuations and uncertainty surrounding interest rates and policy. Additionally, recent adjustments to projected earnings, including a 10% reduction in the 2025 EPS estimate, suggest a more cautious outlook, especially following a significant decline in stock value year-to-date.
This aggregate rating is based on analysts' research of Piper Sandler Cos and is not a guaranteed prediction by Public.com or investment advice.
PIPR Analyst Forecast & Price Prediction
Start investing in PIPR
Order type
Buy in
Order amount
Est. shares
0 shares